Augustine Therapeutics raises oversubscribed EUR 78 million / USD 85 million Series A financing round Novo Holdings and Jeito Capital co-led the ...
Augustine Therapeutics have designed a unique next-generation approach to selectively inhibit HDAC6 while preserving its beneficial non-catalytic functions. This novel non-hydroxamate, non ...
Augustine Therapeutics has raised €78 million ($85 million) in first-round funding for a pipeline headed by a candidate for ...
Pharmaceutical Technology on MSN7d
Augustine secures $85m to advance Charcot-Marie-Tooth candidateAugustine Therapeutics has raised €78m ($85m) in funding to support the development of its lead candidate as it enters a ...
By Karen Roman Private equity company Jeito Capital said it is co-leading an oversubscribed €77.7 million (USD 84.8 million) ...
Augustine Therapeutics have designed a unique next-generation approach to selectively inhibit HDAC6 while preserving its beneficial non-catalytic functions. This novel non-hydroxamate, non-hydrazine ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback